人类表皮生长因子受体2阳性肿瘤靶向药物研究进展

Research progress on targeted drugs of human epidermal growth factor receptor 2 positive tumours

人类表皮生长因子受体2(HER-2)是目前研究最为透彻的人类原癌基因之一。研究表明在人类乳腺癌、胃癌、卵巢癌及其它肿瘤中均存在HER-2过表达的现象,这种过表达使其成为药物研发中的理想靶点。与传统的化疗药物相比,靶向药物和抑制剂类药物,能更好地改善患者的预后,提高患者的生存率,安全性和有效性也更加明显。本文综述了HER-2阳性肿瘤靶向药物的研究现状及治疗进展,为HER-2相关药物开发和临床治疗提供有价值的参考。

Human epidermal growth factor receptor 2（HER-2）is one of the most thoroughly studied human proto-oncogene.In previous studies,overexpression of HER-2 was observed in breast,ovarian,gastric,and many other cancers,as a result,which became the ideal target of drug development.Compared with traditional chemotherapy drugs,targeted drugs and inhibitors could better improve the patients prognosis and survival rate,as well as the safety and efficacy.This paper summarizes the research status of HER-2 positive tumors targeted drugs and treatment progress,which can provide useful references for HER-2 drug development and clinical treatment.